Events
Interact with Decipher Biosciences experts at conferences, tradeshows, and online events to keep current on the latest news and developments.
Filter by:

Interesting ASCO 2020 Decipher sessions:
Friday, May 29
- Abstract 5521
Dr. Fred Saad
Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN
Abstract 5535
Dr. Felix Feng
Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN
Abstracts
Choose a
meeting
American Urological Association (AUA)
AUA 2019 - Chicago, IL
A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome
Response to Apalutamide (APA) among patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN by Decipher Genomic Classifier (GC) score
Genomic expression and prognostic significance of stromal microenvironment in primary prostate cancer
Decipher Biopsy genomic test related to Gleason grade group independent of prostate imaging reporting and data system version 2
A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy
Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy
Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of Decipher and PAM50 tests among different age groups
Correlation between MRI phenotypes and a genomic classifier of prostate cancer
Prospective randomized trial of gene expression classifier utility in men at high risk of recurrence following radical prostatectomy
HOXB13 expression and its role in prostate cancer progression and neuroendocrine differentiation
Impact of SPOP mutation on prostate cancer prognosis
Network-based transcriptomic analysis identifies gene signatures associated with mpMRI-visible prostate cancer
ASCO Genitourinary Cancers Symposium
ASCO GU 2019 - San Fransisco, CA
Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of decipher and PAM50 TESTS among different age groups
A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy
Genomic validation of three-tiered sub-classification of high-risk prostate cancer
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial
Genomic biomarkers to predict outcome in Gleason Score 9-10 disease
ASCO GU 2020 - San Fransisco, CA
Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial
Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED
Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy
Association of an immune-gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC)
Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC)
Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design
Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests
INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer
Tumor cell intrinsic androgen biosynthesis by 3β-hydroxy steroid dehydrogenase (HSD3B1) to modulate radiosensitivity in prostate cancer cells
Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis
American Society for Radiation Oncology
ASTRO 2019 - Chicago, IL
Clinical-genomic Risk Group Classification of Suspicions Lesions on Prostate mpMRI
Associations of Stromal Infiltration with Prognosis and Response to Postoperative Radiotherapy in Prostate Cancer
Integrated Radiogenomic Subtyping and Treatment Response of Intermediate and High Risk Prostate Cancer
Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery
First Prospective Results Assessing the Clinical Utility and Clinical Benefit of Genomic Classifier Testing in Men Post-Prostatectomy